NV-5138 study for treatment-resistant depression in adults
About this title
Read the official source — NCT05066672This study evaluated the safety and effectiveness of NV-5138 for people with depression.
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of NV-5138 for people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
- Listed locations
- BellevueSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 250
- Sponsor
- Navitor Pharmaceuticals, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT05066672
- Official title
Show the full official title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-5138 in Adults With Treatment Resistant Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Bellevue
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of NV-5138 for people with depression.
Who is behind this study?
The study sponsor is Navitor Pharmaceuticals, Inc.
Did this study involve medication?
Yes. The study involved medication, including NV-5138 and matched placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
